ABSTRACT
Bone diseases are monitored with Technetium-99 Methylene di Phosphonate (Tc-99m MDP) as a standard in nuclear medicine. With the prevalence of positron emission tomography/computed tomography (PET/CT) devices all over the world, the use of F-18 NaF for this purpose has come to the fore. Whole body bone scintigraphy with Tc-99m MDP is still used as an established method in many benign and malignant bone diseases because of its acceptable sensitivity and accuracy rates, lower whole body radiation dose than F-18 NaF PET/CT, easier to obtain and cheaper. On the other hand, with its high sensitivity and specificity, F-18 NaF PET/CT should be reserved for some situations where early diagnosis is critical in survival or treatment planning, treatment response needs to be evaluated in the early period, or where a clear distinction between benign and malignant cannot be made with the Tc-99m MDP method.
References
1Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962;3:332-334.
2March 10, 2000. Federal Register 65:12999-13009.
3Eberlein U, Bröer JH, Vandevoorde C, et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a review. Eur J Nucl Med Mol Imaging 2011;38:2269-2281.
4Weber DA, Greenberg EJ, Dimich A, et al. Kinetics of radionuclides used for bone studies. J Nucl Med 1969;10:8-17.
5Blake GM, Park-Holohan SJ, Cook GJ, et al. Quantitative studies of bone with the use of F18-Fluoride and Tc99m-methylene diphosphanate. Semin Nucl Med 2001;1:28-49.
6Hoh CK, Hawkins RA, Dahlbom M, et al. Whole body skeletal imaging with [18F] fluoride ion and PET. Journal of computer assisted tomography 1993;17:34-41.
7Tateishi U, Morita S, Taguri M, et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med 2010;24:523-531.
8Araz M, Aras G, Küçük ÖN. The role of 18F-NaF PET/CT in metastatic bone disease. J Bone Oncol 2015;4:92-97.
9Segall G, Delbeke D, Stabin MG, et al. SNM Guideline for Sodium 18F-Fluoride PET/CT Bone Scans. The Journal of Nuclear Medıcıne 2010;51:1813-1820.
10Jadvar H, Desai B, Ji L, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 2012;37:637-643.
11Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001;31:50-61.
12Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine -18-fluoride PET. J Nucl Med 1997;38:1970-1976.
13Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800-1804.
14Petrén-Mallmin M, Andréasson I, Ljunggren O, et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998;27:72-76.
15Piccardo A, Altrinetti V, Bacigalupo L, et al. Detection of metastatic bone lesions in breast cancer patients: fused (18)F-Fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience. Eur J Radiol 2012;81:2632-2638.
16Kulshrestha RK, Vinjamuri S, England A, et al. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer. J Nucl Med Technol 2016;44:217-222.
17Bortot DC, Amorim BJ, Oki GC, et al. ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:1730-1736.
18Damle NA, Bal C, Bandopadhyaya GP, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 2013;31:262-269.
19Withofs N, Grayet B, Tancredi T, et al. ¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011;32:168-176.
20Bastawrous S, Bhargava P, Behnia F, et al. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. Radiographics 2014;34:1295-1316.
21Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-2389.
22Peterson LM, O’Sullivan J, Wu QV, et al. Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. J Nucl Med 2018;59:1823-1830.
23Hillner BE, Siegel BA, Hanna L, et al. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med 2015;56:222-228.
24Sheikhbahaei S, Jones KM, Werner RA, et al. 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Ann Nucl Med 2019;33:351-361.
25Apolo AB, Lindenberg L, Shih JH, et al. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. J Nucl Med 2016;57:886-892.
26Cook G Jr, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res 2011;1:4.
27Wondergem M, van der Zant FM, van der Ploeg T, et al. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 2013;34:935-945.
28Kjölhede H, Ahlgren G, Almquist H, et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012;110:1501-1506.
29Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011;55:448-457.
30Zacho HD, Jochumsen MR, Langkilde NC, et al. No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy. J Nucl Med 2019;60:1713-1716.
31Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 2010;31:637-645.
32Krüger S, Buck AK, Mottaghy FM, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009;36:1807-1812.
33Even-Sapir E, Metser U, Flusser G, et al Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004;45:272-278.
34Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999;40:1623-1629.
35Ota N, Kato K, Iwano S, et al. Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol 2014;87:20130444.
36Schirrmeister H, Buck A, Guhlmann A, et al. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid 2001;11:677-683.
37Chakraborty D, Bhattacharya A, Mete UK, et al. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med 2013;38:616-621.
38Even-Sapir E, Mishani E, Flusser G, et al. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomohraphy. Semin Nucl Med 2007;37:462-469.
39Iagaru A, Minamimoto R. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. PET Clin 2018;13:383-393.
40Dashevsky BZ, Goldman DA, Parsons M, et al. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging 2015;42:1666-1673.
41Minamimoto R, Loening A, Jamali M, et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med 2015;56:1862-1868.
42 Ida SI, Minamimoto R, Taviani V, et al. Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/MRI. J Nucl Med 2017;58(Suppl 1):755.
43Fourquet A, Rosenberg A, Mena E, et al. A comparison of 18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer. J Nucl Med 2021:jnumed.121.262371.
44Zhou J, Gou Z, Wu R, et al. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol 2019;48:1915-1924.
45Chan SC, Wang HM, Ng SH, et al. Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients. J Nucl Med 2012;53:1730-1735.
46Zhang Y, Chen Y, Huang Z, et al. Comparison of 18F-NaF PET/CT and 18F-FDG PET/CT for detection of skull-base invasion and osseous metastases in nasopharyngeal carcinoma. Contrast Media Mol Imaging 2018;2018:8271313.
47Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012;14:252-259.
48Cai L, Chen Y, Huang Z, et al Incidental Detection of Solitary Hepatic Metastasis by 99mTc-MDP and 18F-NaF PET/CT in a Patient With Osteosarcoma of the Tibia. Clin Nucl Med 2015;40:759-761.
49Chou YH, Ko KY, Cheng MF, et al. 18F-NaF PET/CT Images of Cardiac Metastasis From Osteosarcoma. Clin Nucl Med 2016;41:708-709.
50Rohren EM, Etchebehere EC, Araujo JC, et al. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med 2015;56:1507-1512.
51Collantes M, Martínez-Vélez N, Zalacain M, et al. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET. BMC Cancer 2018;18:1193.
52Kairemo K, Rohren EM, Anderson PM, et al. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open 2019;4:e000439.
53Beheshti M, Mottaghy FM, Paycha F, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging 2015;42:1767-1777.
54Reilly CC, Raynor WY, Hong AL, et al. Diagnosis and Monitoring of Osteoporosis With 18F-Sodium Fluoride PET: An Unavoidable Path for the Foreseeable Future. Semin Nucl Med 2018;48:535-540.
55Zhang V, Koa B, Borja AJ, et al. Diagnosis and Monitoring of Osteoporosis with Total-Body 18F-Sodium Fluoride-PET/CT. PET Clin 2020;15:487-496.
56Frost ML, Fogelman I, Blake GM, et al. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res 2004;19:1797-1804.
57Rhodes S, Batzdorf A, Sorci O, et al. Assessment of femoral neck bone metabolism using 18F-sodium fluoride PET/CT imaging. Bone 2020;136:115351.
58Frost, ML, Cook, GJ, Blake, GM, et al. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res 2003;18:2215-2222.
59Frost ML, Siddique M, Blake GM, et al. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res 2011;26:1002-1011.
60Cook GJ, Blake GM, Marsden PK, et al. Quantification of skeletal kinetic indices in Paget’s disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res 2002;17:854-859.
61Park EK, Pak K, Park JH, et al. Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study. Rheumatol Int 2017;37:765-773.
62Gram SB, Hess S, Ahlquist P, et al. [18F]Sodium fluoride positron emission tomography/computed tomography: a predictor of early rheumatoid arthritis? A case report. Scand J Rheumatol 2018;47:425-426.
63Strobel K, Fischer DR, Tamborrini G, et al. 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging 2010;37:1760-1765.
64Idolazzi L, Salgarello M, Gatti D, et al. 18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity. Ann Nucl Med 2016;30:430-434.
65Watanabe T, Takase-Minegishi K, Ihata A, et al. (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. Mod Rheumatol 2016;26:180-187.
66Jonnakuti VS, Raynor WY, Taratuta E, et al. A novel method to assess subchondral bone formation using [18F]NaF-PET in the evaluation of knee degeneration. Nucl Med Commun 2018;39:451-456.
67Kim K, Son SM, Goh TS, et al. Prediction of Response to Tumor Necrosis Value-alpha Blocker Is Suggested by (18)F-NaF SUVmax But Not by Quantitative Pharmacokinetic Analysis in Patients with Ankylosing Spondylitis. AJR Am J Roentgenol 2020;214:1352-1358.
68 Lee SJ, Kim JY, Choi YY, et al. Predictive value of semi-quantitative index from F-18-fluoride PET/CT for treatment response in patients with ankylosing spondylitis. Eur J Radiol 2020;129:109048.
